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CK2 is a highly conserved protein kinase with growth-promoting and oncogenic properties. It is known to
activate RNA polymerase III (PolIII) transcription in Saccharomyces cerevisiae and is shown here to also exert
a potent effect on PolIII in mammalian cells. Peptide and chemical inhibitors of CK2 block PolIII transcription
in human cell extracts. Furthermore, PolIII transcription in mammalian fibroblasts is decreased significantly
when CK2 activity is compromised by chemical inhibitors, antisense oligonucleotides, or kinase-inactive
mutants. Coimmunoprecipitation and cofractionation show that endogenous human CK2 associates stably and
specifically with the TATA-binding protein-containing factor TFIIIB, which brings PolIII to the initiation site
of all class III genes. Serum stimulates TFIIIB phosphorylation in vivo, an effect that is diminished by
inhibitors of CK2. Binding to TFIIIC2 recruits TFIIIB to most PolIII promoters; this interaction is compro-
mised specifically by CK2 inhibitors. The data suggest that CK2 stimulates PolIII transcription by binding and
phosphorylating TFIIIB and facilitating its recruitment by TFIIIC2. CK2 also activates PolI transcription in
mammals and may therefore provide a mechanism to coregulate the output of PolI and PolIII. CK2 provides
a rare example of an endogenous activity that operates on the PolIII system in both mammals and yeasts. Such
evolutionary conservation suggests that this control may be of fundamental importance.
Protein kinase CK2 (formerly known as casein kinase II) is
ubiquitous and highly conserved in eukaryotes (reviewed in
references 1 and 29). It phosphorylates proteins on serine and
threonine in both the nucleus and the cytoplasm. CK2 exists as
a tetramer, composed of two isozymic catalytic subunits,  and
, and two copies of a regulatory  subunit or one copy each
of  and the closely related . The CK2 and CK2 subunits
are nearly 90% identical and can compensate for each other,
but there is also some functional specialization (57, 69). The 
subunits allow optimal kinase activity and can regulate sub-
strate specificity; they form a stable dimer linking the two
catalytic subunits, which do not contact each other (35).
Although its signaling function has long remained obscure,
CK2 has been shown recently to form part of the Wnt pathway
in both Drosophila and mammals (54, 65). Many studies have
found that increases in the level and/or activity of CK2 are
associated with cell growth and proliferation (for example,
references 3, 4, 7, 25, 30, 34, and 39). Thus, CK2 expression can
be increased by mitogens (7, 39), and CK2 is most abundant in
cells with high mitotic activity, such as transformed cells and
normal colorectal mucosa (34). Indeed, microinjection of CK2
can induce immediate-early gene expression in the absence of
growth factors (11). Conversely, inactivation of CK2 by specific
antibodies or antisense oligonucleotides can arrest the prolif-
eration of primary human fibroblasts (41, 42). Similarly, cell
cycle progression is blocked in Saccharomyces cerevisiae when
temperature-sensitive CK2 mutants are cultured at the non-
permissive temperature (17). Inactivation of CK2 is also lethal
in Schizosaccharomyces pombe and Caenorhabitis elegans (10,
53).
A growth-promoting role for CK2 is consistent with reports
that link it with tumorigenesis. One of the first came from
analysis of theileriosis, a bovine leukemia-like condition
caused by the protozoan Theileria parva. This parasite infects
and transforms lymphocytes, causing them to proliferate out of
control, eventually killing the infected animal due to over-
whelming lymphocytosis (37). The infected cells show a
marked and specific elevation of CK2 activity, but tyrosine
kinases and other signaling pathways are not deregulated (38).
CK2 is abnormally active in a variety of human cancers, in-
cluding leukemias and solid tumors (9, 34, 36). Both of the
CK2 catalytic subunits were found to cooperate with Ras in
transforming primary rat fibroblasts (39), although the con-
verse result was reported for CK2 in NIH 3T3 cells (19).
Direct evidence that CK2 has oncogenic activity comes from
transgenic mice overexpressing the  subunit, which develop
lymphomas from 6 months of age with an incidence of 15 to
20% per year (49). The latency of onset and the monoclonality
of the lymphomas indicate that other mutations are required
for transformation in a multistep process. However, combining
the CK2 transgene with a Myc transgene results in polyclonal
neonatal leukemia, suggesting that deregulation of these two
genes can be sufficient to transform lymphoid cells (67). Sim-
ilarly, leukemogenesis is accelerated dramatically by transgenic
coexpression of CK2 and tal-1 (24). A CK2 transgene also
accelerates lymphoma development in p53-deficient transgenic
mice (26, 67).
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A variety of substrates have been identified for CK2, includ-
ing several oncogene products (31). In S. cerevisiae, CK2 has
been shown to stimulate the synthesis of tRNA and 5S rRNA
by RNA polymerase III (PolIII) (20). This activity may con-
tribute to its growth-promoting activity, since a high rate of
tRNA and rRNA production is associated with rapid growth.
When a yeast strain carrying a temperature-sensitive version of
CK2 is shifted to the nonpermissive temperature, both
growth and PolIII transcription are inhibited specifically (20).
The transcriptional defect can be reproduced in vitro by using
extracts prepared from the mutant strain (14, 15, 20). The
addition of the PolIII-specific factor TFIIIB is sufficient to
restore transcription in CK2 mutant cell extracts (14). This
effect is abolished when TFIIIB is pretreated with phosphatase
(14). These observations led to the proposal that CK2 stimu-
lates PolIII transcription in yeast cells by phosphorylating and
activating TFIIIB (14). In support of this proposal, a popula-
tion of CK2 molecules cofractionates and coimmunoprecipi-
tates with yeast TFIIIB (15).
TFIIIB is a complex composed of the TATA-binding protein
(TBP) and the two associated subunits, B and BRF (reviewed
in references 12, 40, and 59). It plays an essential role in PolIII
transcription, by recruiting the polymerase and positioning it
over the initiation site (23). The  subunit of Saccharomyces
CK2 binds to TBP (15). Furthermore, CK2 phosphorylates
yeast TBP efficiently and enhances its ability to stimulate tran-
scription in a CK2 mutant cell extract (14, 15). Ghavidel and
Schultz concluded that CK2 regulates PolIII activity by phos-
phorylating the TBP subunit of TFIIIB (14). Recruitment of
TFIIIB to a tRNA gene promoter is deficient in an extract
from CK2 mutant cells (15). Promoter association is also
severely impaired following phosphatase treatment of TFIIIB
(15), suggesting that phosphorylation by CK2 in yeast cells
stimulates TFIIIB assembly into a transcription complex.
We demonstrate that CK2 is also required for active mam-
malian PolIII transcription. Inhibiting human CK2 specifically
compromises the binding of TFIIIB to the assembly factor
TFIIIC2, an interaction which is necessary to bring TFIIIB
onto most PolIII templates. This scenario can explain the ob-
servation with yeast cells that CK2 is required for promoter
recruitment of TFIIIB. We also demonstrate that human CK2
interacts stably with TFIIIB. We provide the first evidence that
BRF is phosphorylated in cells and show that CK2 inhibitors
can decrease this phosphorylation. The data suggest that CK2
plays a major role in stimulating the synthesis of PolIII prod-
ucts in mammals by binding and phosphorylating TFIIIB,
thereby promoting transcription complex assembly. These data
provide a rare example of a transcriptional control mechanism
that operates on the PolIII system in both yeast and mammals.
The fact that it has been conserved through evolution argues
strongly for its functional importance. PolIII is responsible for
about 10% of all nuclear transcription, including the synthesis
of tRNA and 5S rRNA; through its potent effect on PolIII
activity, CK2 is likely to have a very major impact on the
biosynthetic capacity of cells. This scenario may help explain
the oncogenic properties of CK2 in mammalian systems.
MATERIALS AND METHODS
Cell culture, transfection, and labeling. A31 and Rat1A are mouse and rat
fibroblast cell lines, respectively, which were grown in Dulbecco’s modified Ea-
gle’s medium (Gibco) supplemented with 10% fetal calf serum (FCS) and anti-
biotics. IMR-90 cells are human diploid fibroblasts which were grown in McCoy’s
medium supplemented with 20% FCS and antibiotics. RS2.31, RS3.22, GV7.21,
and GV13.35 are derivatives of the human osteosarcoma line U2OS which stably
express combinations of CK2 subunits; their production and culturing have been
described elsewhere (57).
CHO cells were cultured in Ham’s F-12 medium supplemented with 10%
heat-inactivated FCS and antibiotics. Hemagglutinin (HA)-tagged BRF was in-
troduced by transient transfection of pcDNA3HA.BRF with Lipofectamine 48 h
prior to labeling. Labeling was carried out with 0.25 mCi of [32P]orthophosphate/
ml in phosphate-free medium for 3 h. After incubation, cells were washed twice
in ice-cold phosphate-buffered saline and then solubilized in 0.5 ml of IP buffer
(50 mM HEPES [pH 7.5], 5 mM EDTA, 10 mM sodium phosphate, 10 mM NaF,
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS], 0.5 mM phenylmethylsulfonyl fluoride, 0.5 g of leupep-
tin/ml, 0.7 g of pepstatin/ml, 0.5 g of aprotinin/ml, 40 g of bestatin/ml, 1 mM
sodium vanadate, 50 mM -glycerophosphate). After 60 min on a rotating wheel,
insoluble material was removed by centrifugation at 14,000  g for 15 min prior
to immunoprecipitation.
Northern blotting. Total cellular RNA was extracted with TRI reagent (Sig-
ma) according to the manufacturer’s instructions. Agarose gel electrophoresis,
Northern transfer, and hybridization were carried out as previously described (6).
The B2 gene and acidic ribosomal phosphoprotein P0 (ARPP P0) gene probes
have been described elsewhere (47).
Cell extraction and fractionation. HeLa cell nuclear extracts were purchased
from the Computer Cell Culture Center (Mons, Belgium). Whole-cell extracts
were prepared from U2OS derivatives by a previously described method (61).
Phosphocellulose columns were run as previously described; PC-B is a 0.1 to 0.35
M KCl step fraction containing TFIIIB and PolIII, and PC-C is a 0.35 to 0.6 M
KCl step fraction containing TFIIIC and PolIII (48). Bacterially expressed re-
combinant CK2 was obtained from New England Biolabs.
Transcription assays. Transcription reactions were carried out as previously
described (62, 63), except that pBR322 was not included and the incubations
were done for 60 min at 30°C. The pVA1 and pLeu template plasmids contain
the adenovirus VA1 gene and a human tRNALeu gene, respectively (61).
Antisense treatment and RT-PCR. Phosphorothioate oligonucleotides (sense,
5-GACGTGAAGATGAGCAGCTC-3; antisense, 5-GAGCTGCTCATCTTC
ACGTC-3) were incubated with cells for 20 h at 100 g/ml prior to harvesting
of RNA. Reverse transcription (RT)-PCR was carried out as previously de-
scribed (66).
Antibodies and Western blotting. Peptide antisera 128 and 330 against BRF
and antiserum 4286 against TFIIIC were described and characterized previ-
ously (2, 6, 28, 55). Antiserum against the BN51 subunit of PdIII was generously
provided by Michael Ittmann (22). CK2 antibody C40420 was purchased from
Affiniti Research Products. Retinoblastoma protein (RB) antibody C-15, CK2
antibody H-286, HA tag antibody F-7, Myc antibody 9E10, and TAFI48 antibody
M-19 were obtained from Santa Cruz Biotechnology. Western immunoblotting
was performed as previously described (61).
Immunoprecipitation. Whole-cell extract (150 g) was incubated at 4°C on an
orbital shaker with 20 l of protein A-Sepharose beads carrying equivalent
amounts of prebound immunoglobulin G. Samples were then pelleted, superna-
tants were removed, and the beads were washed five times with 150 l of LDB
buffer. The bound material was analyzed by Western blotting. Reticulocyte lysate
(Promega) was used to synthesize BRF in the presence of [35S]Met and [35S]Cys,
according to the manufacturer’s specifications, and then was mixed with nuclear
extract prior to immunoprecipitation (see Fig. 8A). In this instance, the precip-
itated material was analyzed by autoradiography rather than Western blotting.
When immunoprecipitation was carried out after transfection, Rat1A cells
were washed with phosphate-buffered saline and then scraped into microextrac-
tion buffer (20 mM HEPES [pH 7.8], 450 mM NaCl, 50 mM NaF, 25% glycerol,
0.2 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride,
0.5 g of leupeptin/ml, 0.7 g of pepstatin/ml, 1.0 g of trypsin inhibitor/ml, 0.5
g of aprotinin/ml, 40 g of bestatin/ml) containing 1 mM sodium vanadate, 50
mM -glycerophosphate, and 0.5% Triton X-100. After incubation on ice for 15
min, the lysates were cleared by centrifugation at 4°C for 10 min in a microcen-
trifuge and then used for immunoprecipitation.
RESULTS
CK2 inhibitors abolish PolIII transcription in human cell
extracts. To begin to investigate whether CK2 regulates mam-
malian PolIII transcription, we tested whether blocking CK2
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activity could influence the level of tRNA synthesis by using
fractionated HeLa cell extracts. For this, we used a substrate
peptide carrying a consensus CK2 phosphorylation site which
has been shown to act as a competitive inhibitor (58). We
confirmed that recombinant human CK2 phosphorylates this
peptide efficiently, without recognizing two control peptides
containing phosphoacceptor sites of alternative serine/threo-
nine kinases (data not shown). As further evidence of speci-
ficity, we confirmed that the CK2 substrate peptide is not
recognized by recombinant glycogen synthase kinase 3 (data
not shown). PolIII transcription was found to decrease by up to
90-fold after preincubation of HeLa cell fractions with the CK2
phosphoacceptor peptide (Fig. 1A). This effect was highly spe-
cific, since expression was virtually unaffected by equal
amounts of peptides bearing consensus phosphoacceptor sites
for Cdc2 or protein kinase A (PKA). Efficient and specific
PolIII repression was also observed when the CK2 peptide was
used with a VA1 gene template and unfractionated HeLa cell
extracts (Fig. 1B). As well as the lack of effect with PKA or
Cdc2 peptides, specificity was also indicated by the fact that
repression with the CK2 peptide could be reversed by using
recombinant CK2 (Fig. 1B, lanes 3 to 5). Although blocking
endogenous CK2 activity clearly inhibited PolIII transcription,
little or no stimulation was observed when recombinant CK2
was added to extracts in the absence of the peptide (Fig. 1B,
lanes 1 to 3). This result can be explained if the endogenous
CK2 activity is already saturating. The data suggest that HeLa
cell extracts contain an excess of CK2 that contributes signif-
icantly to the level of PolIII transcription in vitro.
As an alternative to using peptides, we also examined the
effect of several well-characterized chemical reagents that are
known to inhibit CK2. Transcription of a human tRNALeu
gene was severely repressed by 2,3-diphosphoglycerate (DPG)
and quercetin (Fig. 1C). This response was dose dependent
and was observed at concentrations that have been shown to
inhibit CK2 phosphorylation of established natural substrates,
FIG. 1. Human PolIII transcription is repressed specifically by pep-
tide and chemical inhibitors of CK2. (A) Transcription using HeLa cell
PC-B (2 g) and PC-C (0.7 g) fractions and a pLeu template (250 ng)
after preincubation for 15 min at 30°C with buffer (lanes 1, 6, and 11)
or 10, 20, 30, or 40 g of CK2 phosphoacceptor peptide (RRREEET
EEE; lanes 2 to 5, respectively), PKA phosphoacceptor peptide
(LRRASLG; lanes 7 to 10, respectively), or Cdc2 phosphoacceptor
peptide (RRRPMSPKKKA; lanes 12 to 15, respectively). (B) Tran-
scription using a HeLa cell nuclear extract (15 g) and a pVA1 tem-
plate (250 ng) after preincubation for 15 min at 30°C with buffer (lanes
1, 3, and 6) or 30 g of CK2 phosphoacceptor peptide (lanes 4 and 5)
or PKA phosphoacceptor peptide (lanes 7 and 8). Reaction mixtures
also contained 1 l of recombinant CK2 (lanes 2, 5, and 8) or the
corresponding buffer. (C) Transcription using a HeLa cell nuclear
extract (15 g) and a pLeu template (250 ng) after preincubation for
15 min at 30°C with buffer (lanes 1, 4, 5, and 8), with 6 and 12 mM
2,3-diphosphoglycerate (lanes 2 and 3, respectively), or with 50 and 100
M quercetin (lanes 6 and 7, respectively).
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including yeast TFIIIB (20, 56). PolIII transcription of
tRNAPro, B2, and 5S rRNA genes was also repressed by DPG
and quercetin (data not shown). A third compound that inhib-
its CK2 activity is the ATP analogue 5,6-dichloro-1--D-ribo-
furanosylbenzimidazole (DRB) (52). Like DPG and quercetin,
DRB was found to reduce the rate of PolIII transcription in a
HeLa cell extract (data not shown). Again, the response was
dose dependent and occurred within a micromolar concentra-
tion range that is known to be effective against CK2 (52).
Indeed, we confirmed that human CK2 activity was inhibited
by these chemicals at the concentrations used in the transcrip-
tion assays (data not shown). The selective CK2 inhibitor api-
genin (54) also suppressed transcription by PolIII (data not
shown). We conclude that the expression of class III genes with
human factors in vitro can be influenced strongly by four un-
related compounds that function as inhibitors of CK2 kinase.
Indeed, very little expression is observed under conditions in
which the kinase is inhibited.
CK2 inhibitors reduce the expression of class III genes in
mammalian fibroblasts. Low doses of quercetin and DRB
were also applied to living cells to test for an effect on PolIII
activity in vivo. The addition of 10 M quercetin to prolifer-
ating murine fibroblasts caused a marked decrease in the ex-
pression of PolIII transcripts from the B2 middle repetitive
gene family (Fig. 2A, top). This effect was specific, since there
was little or no change in the expression of a control PolII
transcript encoding ARPP P0 (Fig. 2A, bottom). Very similar
results were obtained with 10 M DRB, suggesting that these
inhibitors influence PolIII activity through the same molecular
mechanism. After normalization to the ARPP P0 control, B2
RNA levels in proliferating cells were found to drop by 2.3-fold
in response to quercetin and by 2.2-fold in response to DRB
(Fig. 2B). In contrast, neither compound made more than a
12% difference in the low basal level of B2 expression detected
in resting cells. Measurements of thymidine incorporation into
newly synthesized DNA showed that the low doses of inhibi-
tors used in these experiments were insufficient to cause sub-
stantial cell cycle arrest when added to proliferating fibroblasts
(data not shown). Additional experiments extended these ob-
servations to include HeLa cells, tRNA genes, and the CK2
inhibitor apigenin (data not shown).
Overexpression of kinase-dead CK2 mutants reduces PolIII
transcription. Vilk and coworkers constructed a series of sta-
ble human osteosarcoma cell lines which overexpress, in a
tetracycline-regulatable manner, CK2 along with either
CK2 or CK2; in addition, they made corresponding lines in
which the catalytic subunits carry an inactivating substitution
(57). We prepared extracts from these cells grown in the pres-
ence or absence of tetracycline. Western blotting confirmed
that in each instance, tetracycline induced the regulatory 
subunit and the wild-type or mutant  or  subunit (data not
shown). Transcription assays carried out with these extracts
showed that overexpressing wild-type CK2 made little differ-
ence to VA1 gene transcription by PolIII (Fig. 3, lanes 1 to 4).
This result may reflect the fact that these tumor cells have high
endogenous CK2 levels even without induction of the trans-
fected constructs (57). However, induction of the kinase-dead
mutants resulted in a significant reduction in VA1 gene tran-
scriptional activity (Fig. 3, lanes 5 to 8). This result probably
reflects interference of the mutants with the activity of the
endogenous kinase. These data provide further evidence that
mammalian PolIII transcription is sensitive to CK2 kinase ac-
tivity. Overproduction of the CK2 mutant causes a signifi-
cant decrease in the rate of cell proliferation (57), an effect
which may contribute to the reduction in PolIII activity. How-
ever, cells overexpressing the CK2 mutant proliferate nor-
mally (57), a fact which rules out the possibility of an indirect
growth effect influencing PolIII transcription in this situation.
The observed reduction in class III gene transcription might be
expected to slow cell growth and proliferation; however, pa-
rental osteosarcoma cells have abnormally elevated levels of
PolIII activity, which may allow them to tolerate the reduction
due to the CK2 mutant without it becoming limiting for
growth.
Depletion of CK2 from human cells reduces primary tRNA
FIG. 2. Chemical inhibitors of CK2 reduce the expression of PolIII
transcripts in proliferating murine fibroblasts. (A) Northern blot anal-
ysis of total RNA (10 g) from A31 cells cultured in 0.5% serum (lanes
1, 3, and 5) or 20% serum (lanes 2, 4, and 6) and treated with 10 M
quercetin (lanes 3 and 4) or 10 M DRB (lanes 5 and 6). The upper
panel shows the blot probed with a B2 gene; the lower panel shows the
same blot that has been stripped and reprobed with an ARPP P0 gene.
(B) The B2 signals were quantified and normalized against the ARPP
P0 signals. Means and standard deviations from three independent
experiments are represented graphically.
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transcript levels. The data above provide several independent
lines of evidence that CK2 has a substantial influence on the
mammalian PolIII machinery. Since each of these approaches
involved manipulating kinase activity, it implicated the cata-
lytic subunits of CK2 but did not address whether the regula-
tory  subunit also influences PolIII. To this end, we adopted
a published antisense approach to target CK2 specifically in
vivo (42, 49). An antisense oligonucleotide directed against
mRNA encoding CK2 depleted this subunit from IMR-90
human diploid fibroblasts, whereas the complementary sense
oligonucleotide had little effect (Fig. 4, right). Although the
antisense depletion was incomplete, it exceeded the modest
decrease in CK2 observed after serum starvation. RNA was
harvested from these cells and used to produce cDNAs for
RT-PCR. To assess PolIII activity, we used primers which
hybridize to the introns within unprocessed tRNA precursors;
since these short-lived primary transcripts are spliced very rap-
idly, their levels in a cell provide a reliable indication of ongo-
ing transcription (66). The levels of the RT-PCR products
were not diminished significantly when cells were treated with
the sense oligonucleotide. In contrast, a substantial decrease
was observed for both tRNAArg and tRNATyr following treat-
ment with the antisense oligonucleotide (Fig. 4, left). These
effects were specific, since there was no change in the level of
glyceraldehyde phosphate dehydrogenase mRNA. The data
suggest that the production of PolIII transcripts in vivo is
sensitive to the level of CK2.
Preassembled PolIII transcription complexes are resistant
to CK2 inhibitors. We used order-of-addition experiments to
test whether CK2 acts before or after transcription complex
assembly. When a HeLa cell extract was preincubated with
peptide inhibitors, as in Fig. 1, the CK2 competitor caused a
specific repression of VA1 expression that was not seen with
the PKA control (Fig. 5, lanes 1 to 3). However, in parallel
assays in which the extract was preincubated with template
DNA to allow initiation complex assembly prior to peptide
addition, transcription was no longer inhibited by the CK2
competitor (Fig. 5, lanes 4 to 6). Similarly, quercetin blocked
VA1 expression very efficiently when added before the extract
was mixed with the template but had only a slight effect when
the complex was allowed to preassemble (Fig. 5, lanes 7 to 10).
Indeed, quercetin was 11-fold less effective as an inhibitor
when added to the preformed transcription complex. Identical
results were obtained with DRB as an unrelated CK2 inhibitor
or with a tRNA gene as an alternative template (data not
shown). These observations suggest that CK2 acts specifically
during assembly of the class III machinery; its inhibition ap-
pears not to affect the subsequent initiation, elongation, or
termination steps of transcription. Furthermore, since our as-
say measures multiple rounds of transcription from stable com-
plexes, the data suggest that polymerase recruitment is unaf-
fected by blocking CK2.
Mammalian CK2 interacts stably with endogenous TFIIIB.
Initial experiments to test whether human CK2 associates with
the PolIII machinery revealed the presence of CK2 kinase
activity in TFIIIB fractions that had been affinity purified on
antibody columns; in contrast, fractions containing immunoaf-
finity-purified TFIIIC2 showed only a low level of CK2 activity
that was close to the background level found in mock-purified
controls (data not shown). Since this result suggested that CK2
may interact stably with TFIIIB, we tested for cofractionation
during gradient chromatography. When fractions containing
TFIIIB were subjected to gradient chromatography on hy-
droxyapatite, heparin-Sepharose, or Mono Q columns, TFIIIB
activity was found to coincide with a clear peak of CK2 activity
(data not shown). These effects were specific, since TFIIIB did
not copurify on these columns with PKA, glycogen synthase
kinase 3, or DNA-dependent protein kinase (data not shown).
Although it could be fortuitous, the consistent cofractionation
of CK2 with TFIIIB is suggestive of a stable interaction be-
tween these proteins.
As an independent test of this association, immunoprecipi-
tation experiments were carried out with a HeLa cell extract
and an antibody against CK2. As positive controls, we used an
antibody against the BRF subunit of TFIIIB and an antibody
against the RB protein, which is known to bind to TFIIIB (27).
The negative control was an antibody against the TAFI48 sub-
unit of the PolI-specific factor SL1/TIF-IB. Western blotting
revealed that BRF was coimmunoprecipitated with CK2 and
RB but not with the TAFI48 subunit antibody (Fig. 6A). This
result was confirmed by using a second antibody raised against
a different region of BRF (data not shown). The interaction
between CK2 and TFIIIB is not dependent on the kinase
activity of CK2, since it was undiminished by the presence of
either quercetin or DRB (Fig. 6B). A stable association be-
tween TFIIIB and CK2 was also observed in the converse
experiment, where an antibody against BRF was consistently
found to coimmunoprecipitate CK2 activity from cell extracts
(data not shown). These observations again indicate a stable
and specific association between human TFIIIB and CK2.
CK2 phosphorylates the BRF subunit of TFIIIB. The data
indicate that CK2 binds stably to TFIIIB and that its kinase
activity has a strong stimulatory effect on PolIII transcription
both in vitro and in vivo. The most likely explanation is that
CK2 phosphorylates one or more components of the PolIII
machinery. Indeed, consensus CK2 phosphoacceptor sites are
present in TFIIIC2 and all three subunits of TFIIIB. Further-
more, preliminary analyses showed that TBP, BRF, and B can
FIG. 3. Overexpression of kinase-inactive CK2 mutants reduces
PolIII transcriptional activity. Transcription was analyzed with the
pVA1 template (250 ng) and extracts (20 g) of RS2.31 (lanes 1 and
2), RS3.22 (lanes 3 and 4), GV7.21 (lanes 5 and 6), and GV13.35 (lanes
7 and 8) cells grown in the presence (even-numbered lanes) or absence
(odd-numbered lanes) of tetracycline (Tet). The CK2 catalytic subunit
that is overexpressed in each sample is indicated; in each sample,
CK2 is overexpressed in parallel. mut, mutant.
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all be phosphorylated by purified recombinant CK2 in vitro
(data not shown). Although TBP has already been shown to be
a substrate for phosphorylation (14, 18, 61), there have been no
reports that the TAF components of TFIIIB are also phos-
phorylated. We therefore investigated whether BRF is subject
to phosphorylation in vivo by transfecting into CHO cells a
vector encoding HA-tagged BRF. The transfected cells were
cultured in the presence of high or low serum concentrations.
They were labeled with [32P]orthophosphate, harvested, and
subjected to immunoprecipitation with an anti-HA antibody.
The precipitated material was resolved on a denaturing gel and
subjected to both autoradiography and Western blotting. This
experiment revealed that BRF was phosphorylated in vivo and
that the level of phosphorylation increased 4-fold when the
cells were stimulated to proliferate with serum (Fig. 7, lanes 1
and 2). However, when low doses of quercetin were used to
reduce the activity of CK2 in these fibroblasts, BRF labeling
was decreased by 56% in the proliferating cells (Fig. 7, lanes
4). In contrast, quercetin made only an 15% difference in the
level of BRF phosphorylation in serum-starved cells (Fig. 7,
lanes 3). Western blotting confirmed that equal amounts of
BRF were immunoprecipitated in each instance. Similar re-
sults were obtained when DRB was used instead of quercetin
to inhibit the activity of endogenous CK2 (data not shown).
These findings suggest that CK2 contributes to the phosphor-
ylation of BRF in vivo and that its contribution increases when
cells proliferate.
CK2 promotes interactions between TFIIIB and TFIIIC2.
TFIIIB makes important functional contacts with both PolIII
and TFIIIC2 (12, 40, 59). Coimmunoprecipitation experiments
were carried out to test whether CK2 activity influences these
interactions. The BRF subunit of TFIIIB was 35S labeled by
translation in vitro and then mixed with a HeLa cell extract. In
immunoprecipitation reactions carried out with antiserum
against TFIIIC2, radiolabeled BRF was coprecipitated by vir-
tue of the interaction between these proteins; this effect was
specific, since BRF was not immunoprecipitated when the cor-
responding preimmune serum was used (Fig. 8A, lanes 2 and
3). The association of BRF with TFIIIC2 in this assay was not
DNA mediated, as it was unaffected by the inclusion of
ethidium bromide (data not shown). When quercetin was
added to inhibit CK2 activity, BRF was no longer coprecipi-
tated with TFIIIC2 (Fig. 8A, lane 4). In contrast, quercetin did
not prevent the immunoprecipitation of BRF when anti-BRF
FIG. 4. Depletion of CK2 with an antisense oligonucleotide results in decreased tRNA synthesis in human fibroblasts. (A) PCR amplification
was carried out with tRNAArg (top), tRNATyr (middle), or glyceraldehyde phosphate dehydrogenase (GAPDH) (bottom) primers and cDNAs
prepared from RNAs extracted from IMR-90 cells treated with sense (lane 1), antisense (lane 2), or no (lanes 3 and 4) oligonucleotides and grown
in the presence (lanes 1 to 3) or absence (lane 4) of serum. (B) Extracts (30 g) prepared from IMR-90 cells treated with sense (lane 1), antisense
(lane 2), or no (lanes 3 and 4) oligonucleotides and grown in the presence (lanes 1 to 3) or absence (lane 4) of serum were resolved by
SDS-polyacrylamide gel electrophoresis and then blotted with CK2 antibody C40420.
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antiserum was used (data not shown). The same effect was
observed with the unrelated CK2 inhibitors apigenin and DRB
(Fig. 8A, lane 5, and data not shown). Furthermore, a CK2
inhibitory peptide also blocked the coprecipitation of BRF
with antiserum against TFIIIC2, whereas an equal amount of
control PKA peptide did not (Fig. 8A, lanes 6 and 7). Similarly,
quercetin and DRB could block the coimmunoprecipitation of
TFIIIC2 with antibodies against TFIIIB (data not shown).
These results suggest that phosphorylation by CK2 may be
required for BRF to interact efficiently with TFIIIC2.
To find out whether similar effects occur in vivo, Rat1A cells
were stably transfected with a vector encoding HA-tagged
BRF. When an anti-HA antibody was used to immunoprecipi-
tate lysates of these cells, both TFIIIC2 and PolIII were co-
precipitated with HA-tagged BRF, as revealed by Western
blotting (Fig. 8B, lane 2). This result was due to specific inter-
actions, since little or none of these proteins was detected
when an irrelevant antibody against cyclin A was used in a
negative control immunoprecipitation (Fig. 8B, lane 1). Fur-
thermore, the anti-HA antibody failed to coprecipitate
FIG. 5. Preassembled PolIII transcription complexes are resistant
to CK2 inhibitors. Transcription was analyzed with a HeLa cell nuclear
extract (15 g) and the pVA1 template (250 ng) in the presence of
buffer (lanes 1, 4, 7, and 9), 20 g of CK2 phosphoacceptor peptide
(lanes 2 and 5), 20 g of PKA phosphoacceptor peptide (lanes 3 and
6), or 100 M quercetin (lanes 8 and 10). Lanes 1 to 3, 7, and 8 show
reactions in which the extract was preincubated for 15 min at 30°C with
peptide, buffer, or quercetin prior to the addition of pVA1 and nucle-
otides. Lanes 4 to 6, 9, and 10 show reactions in which the extract was
preincubated for 15 min at 30°C with pVA1 before peptide, buffer, or
quercetin was added with the nucleotides.
FIG. 6. Endogenous TFIIIB is coimmunoprecipitated from HeLa
cells with endogenous CK2. (A) HeLa cell extract (150 g) was im-
munoprecipitated (IP) with anti-BRF antibody 128 (lane 1), anti-RB
antibody C-15 (lane 2), anti-CK2 antibody H-286 (lane 3), or anti-
TAFI48 antibody M-19 (lane 4). Precipitates were resolved by SDS-
polyacrylamide gel electrophoresis and then analyzed by Western blot-
ting with anti-BRF antibody 330. (B) HeLa cell extract (150 g) was
immunoprecipitated in the presence of buffer (lanes 1 and 4), 100 M
quercetin (lanes 2 and 5), or 400 M DRB (lanes 3 and 6) with
anti-CK2 antibody H-286 (lanes 1 to 3) or anti-TAFI48 antibody
M-19 (lanes 4 to 6). Precipitates were resolved by SDS-polyacrylamide
gel electrophoresis and then blotted with anti-BRF antibody 128. IgG,
immunoglobulin G.
VOL. 22, 2002 ACTIVATION OF HUMAN POLIII TRANSCRIPTION BY CK2 3763
 o
n
 January 8, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
TFIIIC2 or PolIII when cells were transfected with an empty
vector encoding the HA tag without BRF attached (data not
shown). When HA-tagged BRF-transfected cells were treated
with quercetin in order to reduce CK2 activity, the amount of
coprecipitated TFIIIC2 was decreased by fivefold (Fig. 8B and
C). This effect was specific, since the interaction between HA-
tagged BRF and PolIII was undiminished (Fig. 8B and D). The
same behavior was seen when DRB was used instead of quer-
cetin to inhibit CK2 (data not shown). The data suggest that
CK2 activity specifically promotes the interaction between
TFIIIB and TFIIIC2 in living mammalian cells.
DISCUSSION
Several independent lines of evidence indicate that CK2
activity is required for efficient transcription of many PolIII
templates in mammals. Unrelated chemical inhibitors specifi-
cally diminish the expression of class III genes in proliferating
fibroblasts and virtually abolish their transcription in vitro
when used at concentrations that block CK2. Transcription by
PolIII in human cell extracts can also be ablated specifically by
a peptide inhibitor of CK2, an effect reversed by recombinant
CK2. Overexpression in human osteosarcoma cells of kinase-
dead mutants of CK2 or CK2 reduces PolIII transcriptional
activity. Furthermore, antisense-mediated depletion of CK2
from human diploid fibroblasts decreases the level of primary
tRNA transcripts. Additional evidence is provided by cofrac-
tionation and coimmunoprecipitation experiments, which re-
veal a stable and specific interaction between HeLa cell CK2
and TFIIIB. On the basis of these combined data, we suggest
that transcription by mammalian PolIII is highly dependent on
CK2. Clearly, this notion has not been established for all types
of class III genes. However, it is likely to be a very general
effect, since it has been found in every example tested (VA1, 5S
rRNA, B2, and several tRNA genes) and involves the interac-
tion between BRF and TFIIIC2, which is considered necessary
for most PolIII transcription. Possible exceptions might be
provided by the U6 and 7SK genes, which do not use either
BRF or TFIIIC2 (12, 40, 46).
The sizes of PolIII transcripts do not change appreciably
when CK2 is inhibited; this fact suggests that inactivation of
the kinase does not interfere with selection of the sites of
transcription initiation or termination. Indeed, primer exten-
sion revealed no change in start site selection following the
addition of CK2 inhibitors (data not shown). We also found no
evidence for effects on the elongation phase of transcription, as
might be revealed by the appearance of short transcripts that
result from premature pausing. These observations are consis-
tent with the results of order-of-addition experiments, which
showed that CK2 acts prior to initiation. We demonstrated that
CK2 inhibitors compromise the interaction between TFIIIB
and TFIIIC2 without affecting the association of TFIIIB with
PolIII. We also found that blocking CK2 activity had no effect
on DNA binding by TFIIIC2 (data not shown). Our data there-
fore implicate a single step in the transcription cycle that re-
sponds to CK2, namely, the recruitment of TFIIIB by DNA-
bound TFIIIC2. Coimmunoprecipitation assays show that CK2
inhibitors severely compromise the binding of endogenous
TFIIIC2 to BRF in vitro and in fibroblasts. This effect is very
selective, since the binding of PolIII to BRF is not compro-
mised by the same treatment. Studies with Saccharomyces have
shown that the binding of BRF to TFIIIC is a rate-limiting step
in PolIII transcription. Moir and colleagues and Rameau and
colleagues demonstrated that transcription can be stimulated,
both in vitro and in vivo, by mutations in TFIIIC131, the
TFIIIC subunit that binds to BRF (33, 44). These mutations
facilitate the recruitment of the latter by a complex mechanism
which, in the case of the PCF1-1 allele, appears to involve a
conformational change in TFIIIC131 that increases its affinity
for BRF (32, 33; R. Moir and I. Willis, personal communica-
tion). The mutations cluster in a discrete region of TFIIIC131
that contains a tetratricopeptide repeat which is conserved in
the human homologue of this subunit (21). Since BRF is also
conserved through evolution (21), a similar rearrangement
may occur in mammals. If so, it would be likely that such a
rate-limiting step is targeted for regulation. Indeed, it was
shown previously that the binding of TFIIIB to TFIIIC2 is
subject to repression by the RB protein in mammalian cells
FIG. 7. BRF is phosphorylated in vivo. (A) CHO cells in 10% FCS
were transiently transfected with pcDNA3HA.BRF (10 g) and la-
beled 48 h later with [32P]orthophosphate for 3 h in the absence (lanes
1 and 2) or presence (lanes 3 and 4) of 20 M quercetin. Cells in
reactions 1 and 3 were transferred to FCS-free medium 24 h before
labeling. Transfected BRF was immunoprecipitated with anti-HA an-
tibody F-7, resolved on an SDS–7.8% polyacrylamide gel, transferred
to nitrocellulose, and then visualized by autoradiography (top) and
Western blotting with F-7 (bottom). (B) Phosphorylated BRF was
quantified and normalized against total immunoprecipitated BRF.
Means and standard deviations from three independent experiments
are represented graphically.
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and that this effect helps mediate cell cycle control (47, 55).
The current study suggests that the same step in preinitiation
complex assembly is also regulated in a positive fashion
through phosphorylation by CK2. This effect appears to have a
very substantial influence on the activity of the mammalian
PolIII machinery.
Several investigators have provided unequivocal evidence
that CK2 stimulates PolIII transcription in Saccharomyces (14,
15, 20). The fact that this role has been maintained through
evolution is consistent with the very high level of phylogenetic
conservation that is displayed by CK2. For example, mouse
CK2 is 99 and 98% identical to the human and chicken
proteins, respectively (39, 68). TFIIIB is the target for CK2
within the yeast PolIII machinery (14), reflecting a stable in-
teraction between these proteins (15). Furthermore, CK2 func-
tion is necessary for yeast TFIIIB to be recruited effectively to
a tRNA gene (15). These findings are all consistent with our
observations of mammals; we found that CK2 associates with
TFIIIB and stimulates its binding to TFIIIC2, the interaction
responsible for recruiting TFIIIB to tRNA genes. However,
within the Saccharomyces TFIIIB complex, only TBP is phos-
phorylated efficiently by purified CK2 in vitro, and Ghavidel
and Schultz (14) concluded that the phosphorylation of TBP is
likely to be responsible for the activation of TFIIIB by CK2.
This conclusion is strongly supported by recent experiments
with TBP mutants in vivo (15). It remains to be determined
how this phosphorylation can influence TFIIIB recruitment or
why the effect is specific to PolIII. In contrast, preliminary data
suggest that all three subunits of human TFIIIB can be phos-
phorylated directly by CK2 in vitro. This notion is consistent
with the presence of consensus CK2 phosphoacceptor se-
quences in human BRF and B, as well as TBP. Furthermore,
we have provided the first evidence that BRF is subject to
phosphorylation in cells. Endogenous CK2 is likely to be partly
responsible, since in vivo labeling of BRF decreases by more
than twofold when proliferating fibroblasts are treated with
low doses of CK2 inhibitors. Since BRF binds directly to
TFIIIC, it is easy to imagine how its phosphorylation might
regulate the recruitment of TFIIIB. However, the phosphory-
lation of TBP or, indeed, B may also influence complex as-
sembly, directly or indirectly.
A previous study found that CK2 inhibits the ability of hu-
man La to stimulate RNA synthesis from isolated PolIII tran-
scription complexes (8). However, our work indicates that CK2
promotes rather than inhibits human PolIII transcription, both
in vitro and in vivo. The reason for this discrepancy is unclear.
FIG. 8. CK2 inhibitors specifically compromise the binding of
TFIIIB to TFIIIC2. (A) A reticulocyte lysate (10 l) containing in
vitro-translated BRF was mixed with a HeLa cell extract (150 g) in
the presence of buffer (lanes 2 and 3), 100 M quercetin (lane 4), 80
M apigenin (lane 5), 40 g of CK2 phosphoacceptor peptide (lane 6),
or 40 g of PKA phosphoacceptor peptide (control) (lane 7). The
mixture was then immunoprecipitated (IP) with anti-TFIIIC anti-
serum 4286 (lanes 3 to 7) or the corresponding preimmune serum
(lane 2). Proteins retained after extensive washing were resolved by
SDS-polyacrylamide gel electrophoresis and visualized by autoradiog-
raphy. Lane 1 shows 10% of the input reticulocyte lysate. (B) Rat1A
cells stably transfected with pcDNA3HA.BRF were lysed and immu-
noprecipitated with anti-cyclin A (Cyc A) antibody (Ab) BF683 (lane
1) or anti-HA antibody F-7 (lanes 2 and 3). Immunoprecipitated ma-
terial was resolved by SDS-polyacrylamide gel electrophoresis and
analyzed by Western blotting with antiserum 4286 against TFIIIC2
(top), anti-BN51 antiserum against PolIII (middle), and antibody F-7
against the HA tag on transfected BRF (bottom). (C) Coprecipitated
TFIIIC2 was quantitated by densitometry and normalized against the
amount of immunoprecipitated HA-BRF. Nonspecific binding to con-
trol antibody was subtracted. The value obtained for vehicle-treated
cells was arbitrarily assigned as 1.0. Values are the means of three
experiments; error bars indicate standard deviations. (D) As for panel
C, except that coprecipitated PolIII was quantitated instead of
TFIIIC2.
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The stimulatory effect that we observed with CK2 is supported
by the observations made in yeast studies (14, 15, 20). It is also
more consistent with the role of CK2 in promoting prolifera-
tion (17, 41, 42), since repression of PolIII transcription would
not be expected in situations of active growth.
PolIII transcription in mammals is subject to a wide variety
of regulatory influences (reviewed in references 5 and 59). For
example, it can respond strongly to cell differentiation (63) and
displays marked cell cycle fluctuations, being repressed during
mitosis and much of G1 and peaking during S and G2 (60).
However, there has been little evidence to date for instances of
PolIII control that cross the evolutionary divide. This fact
seems surprising, since the polymerase and much of the basal
machinery have been fairly well conserved (12, 21). A striking
illustration is provided by growth arrest, which involves the
repression of PolIII transcription both in mammals and in
yeast. When logarithmically growing S. cerevisiae reaches sta-
tionary phase, there is a marked decrease in the level of the
BRF subunit of TFIIIB (50). Even though BRF is conserved
through evolution, its abundance is unaffected when mamma-
lian fibroblasts arrest due to serum deprivation (47). Instead,
genetic and biochemical evidence shows that the RB protein is
primarily responsible for suppressing PolIII transcription in
growth-arrested fibroblasts (47). Thus, very different molecular
mechanisms are used by mammals and yeast to achieve the
same end. In contrast, CK2 displays a potent capacity to acti-
vate PolIII transcription in both yeast and humans. The con-
servation of this control suggests that it may be of fundamental
importance. Indeed, this notion may help explain why CK2 has
been so well conserved through evolution. In light of this im-
portant precedent, we anticipate that some of the other regu-
latory mechanisms that operate on PolIII in S. cerevisiae may
also prove to be relevant to humans. For example, the TOR
kinases stimulate PolIII transcription in yeast (70), and we
have evidence that this signaling pathway can also influence
PolIII activity in mammals (data not shown). In S. cerevisiae,
the PolIII enzyme is bound and repressed by Maf1p, a protein
which displays strong phylogenetic conservation and so may
well prove to function in a similar capacity in metazoans (43).
Unveiling the controls that have been maintained through evo-
lution is likely to provide important insights into the funda-
mentals of PolIII regulation.
Ghavidel and Schultz (15) recently showed that PolIII tran-
scription is repressed when yeast is exposed to genotoxic
stresses (UV or methane methylsulfonate). This result reflects
a loss of TFIIIB activity due to the dissociation of CK2 (15).
Substitution of a CK2 consensus site on the surface of TBP
(S128) compromises the PolIII stress response, suggesting that
TBP phosphorylation provides a major part of this control
(15). Although a serine is found at the corresponding position
of human TBP (S222), its surrounding residues do not match
the CK2 consensus (13). It is possible that this site is never-
theless phosphorylated by CK2, but it is also plausible that
alternative residues and/or polypeptides are functionally sig-
nificant targets for human CK2. When bound to TFIIIB, CK2
may be ideally located to phosphorylate multiple proteins
within the transcription complex. Indeed, CK2 phosphoaccep-
tor sites are common, and all five subunits of TFIIIC2 are
phosphorylated in human cells, although the kinases responsi-
ble have yet to be identified (51). The stimulatory effect of CK2
on the interaction between TFIIIB and TFIIIC2 may involve
the phosphorylation of either or both of these factors. Further
work is required to investigate these possibilities and to test
whether CK2 allows mammalian PolIII to respond to DNA
damage.
CK2 has also been found to stimulate rRNA synthesis by
PolI both in mammals and in yeast (3, 15, 58). This finding may
be of significance for its ability to promote proliferation, since
a high cellular content of rRNA and ribosomes is a prerequi-
site for rapid growth (16, 45). As 5S rRNA is required in
equimolar amounts with the large rRNA molecules, PolIII is
usually coregulated with PolI (40). The fact that CK2 stimu-
lates transcription by both PolI and PolIII suggests that this
kinase may be involved in coordinating the activities of these
two polymerase systems in mammalian cells, perhaps helping
to balance the production of large rRNAs with that of 5S
rRNA. Since PolI and PolIII together are responsible for
80% of nuclear transcription, such a role might make CK2 an
important player in coordinating biosynthetic activity in mam-
mals, perhaps helping to ensure that the supply of tRNA and
rRNA is appropriate for the physiological status of the cells.
Most transformed cell lines and tumors have abnormally
high levels of PolIII activity (5). Various mechanisms may
contribute to this deregulation, but probably the most frequent
is the loss of repression by the tumor suppressor RB, which
binds TFIIIB and blocks its interactions with TFIIIC2 and
PolIII (55). This function is compromised by mutations which
arise naturally in cancers (5, 55, 64), by the binding of viral
oncoproteins (28, 64), and by RB hyperphosphorylation due to
overexpression of cyclin D1 or loss of p16 (47). The discovery
that mammalian CK2 activates PolIII transcription suggests
another potential mechanism that contributes to the overex-
pression of class III genes in certain types of malignancy. It is
notable that the interaction between TFIIIB and TFIIIC2 is
subject to opposing controls by the tumor suppressor RB and
the putative oncoprotein CK2. The balance between these
antagonistic forces will have a major impact on PolIII tran-
scriptional activity and perhaps also on the growth potential of
cells.
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